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Accurate identification of sparse heterozygous single-nucleotide variants (SNVs)
is a critical challenge for identifying the causative mutations in mouse genetic
screens, human genetic diseases and cancer. When seeking to identify causal
DNA variants that occur at such low rates, they are overwhelmed by false-
positive calls that arise from a range of technical and biological sources. We
describe a strategy using whole-exome capture, massively parallel DNA sequen-
cing and computational analysis, which identifies with a low false-positive rate
the majority of heterozygous and homozygous SNVs arising de novo with a
frequency of one nucleotide substitution per megabase in progeny of N-ethyl-
N-nitrosourea (ENU)-mutated C57BL/6j mice. We found that by applying a
strategy of filtering raw SNV calls against known and platform-specific variants
we could call true SNVs with a false-positive rate of 19.4 per cent and an esti-
mated false-negative rate of 21.3 per cent. These error rates are small enough
to enable calling a causative mutation from both homozygous and heterozygous
candidate mutation lists with little or no further experimental validation. The effi-
cacy of this approach is demonstrated by identifying the causative mutation in
the Ptprc gene in a lymphocyte-deficient strain and in 11 other strains with
immune disorders or obesity, without the need for meiotic mapping. Exome
sequencing of first-generation mutant mice revealed hundreds of unphenotyped
rsob.royalsocietypu
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to be deleterious, which now become available for breeding
and experimental analysis. We show that exome sequencing
data alone are sufficient to identify induced mutations. This
approach transforms genetic screens in mice, establishes a gen-
eral strategy for analysing rare DNA variants and opens up a
large new source for experimental models of human disease.blishing.org
Open
Biol2:1200612. Introduction
Genetic traits in mammals have long posed a great challenge
in connecting them to their causal DNA variant. This is
especially true when that variant is a single-nucleotide substi-
tution and is present on only one of the two copies of a
chromosome. Finding such a single-nucleotide substitution
in a genome as large as humans or mice without huge num-
bers of false positives and without reducing the search to a
sub-chromosomal region by meiotic mapping has been an
unattainable goal. Single-nucleotide variants (SNVs) rep-
resent a major source of de novo and inherited genomic
variation in humans, mice and other mammals, and, as
such, new strategies are needed to identify and analyse
these variants accurately on a genome-wide scale.
Genetic analyses of mammalian traits are often performed
in inbred C57BL/6 laboratory mice. These mice have a
known homogeneous reference genome sequence and have
a uniform genetic background that allows experimental
reproducibility and transplantation experiments. In these
mice, treatment with the chemical mutagen N-ethyl-N-
nitrosourea (ENU) efficiently generates random single-base
mutations in the germline DNA (reviewed in [1]). Diseases
and traits resulting from these ENU-induced mutations can
be detected by phenotypic screening procedures relevant to
an area of biological investigation.
The bottleneck of the ENU mutagenesis approach has long
been in identifying a single disease-causing mutation in an
entire genome of possibilities. Until recently, the approach
employed has been arduous: to out-cross affected mice to
another inbred strain and then use a panel of common
strain-specific variants to meiotically map the causal mutation
to a sub-region of an individual chromosome of less than 20
megabases (Mb). Once limited to a relatively short list of pos-
itional candidate genes, PCR amplification of all exons in the
mapped interval followed by Sanger sequencing could then
be performed and variants identified by a combination of
automated and manual review of the sequence traces. This
has proven to be an effective strategy, although it can take
several years and is labour-intensive, expensive and often
confounded by modifier genes introduced during the cross
to another inbred strain.
To date, all but the smallest minority of causative ENU-
induced mutations have been shown to reside in the exonic por-
tion of the genome. Approximately 75 per cent are caused by
SNVs in protein-coding exons that result in missense or non-
sense mutations and the remaining approximately 25 per cent
are SNVs in splice donor–acceptor sites that disrupt correct
mRNA splicing to cause protein truncations, deletions or non-
sense-mediated decay [2]. Hence, sequencing of the exome
rather than the whole genome should identify almost all inter-
esting ENU-induced variants. Array- and solution-based DNA
capture technologies [3,4] can now reliably enrich a DNA
sample for coding regions, enabling massively parallelsequencing to be undertaken on a greatly reduced proportion
of the genome. Exome capture followed by sequencing has
already become an established technique in human genetics
and an early vanguard of reports has identified the genetic
cause of a number of monogenic diseases (reviewed in [5]). In
most of these studies, prior information regarding a general
chromosomal location of the genetic lesion was known,
heritability information was available or a candidate gene
approach was used. One feature of all of these studies was
the difficulty in discerning causative, deleterious mutations
from normal genetic variation and sequencing errors.
In the mouse, early studies [6–8] using slightly different
approaches have identified ENU-induced mutations using
massively parallel sequencing information. Zhang et al. [8]
identified a previously known ENU-induced mutant by
sequencing cloned bacterial artificial chromosomes from a
2.2 Mb genomic region that had first been defined by meiotic
mapping. Arnold et al. [6] applied shallow sequencing of the
entire mouse genome to detect putative mutations and, fol-
lowing this, they performed extensive validation by Sanger
sequencing and meiotic mapping. Yabas et al. [7] mapped a
novel ENU mutation to a region of the X-chromosome, and
identified the mutation by oligonucleotide bait-mediated cap-
ture and deep sequencing of exonic DNA fragments within
this region. Fairfield et al. [9] provided an extensive demon-
stration of the utility of exome capture technology for
identifying both homozygous and heterozygous ENU-
induced and spontaneous mutations in nine mouse strains.
However, in all cases these studies relied on at least coarse
meiotic mapping information or considerable validation of
SNV calls to identify the causative mutation. Fairfield et al.
[9] suggest that an exome sequence as a sole source of infor-
mation may not be enough to identify disease-causing
induced mutations without extensive SNV validation.
In this study, we have investigated whether exome capture
followed by sequencing provides sufficient information alone
to reliably identify the rare, ENU-induced, de novo mutations
in C57BL/6j mice. We generated exome datasets for 12 mutant
mouse strains, including a matched technical and biological
replicate dataset for one strain. We present methodology
developed to identify both homozygous and heterozygous
ENU-induced mutations and use this to identify 12 primary
causative mutations and two disease-causing incidental
mutations. We also reveal hundreds of potentially deleterious
ENU mutations in first-generation (G1) mice that are immedi-
ately available for phenotypic and experimental analysis in
their progeny. Our results demonstrate that exome sequencing
provides highly reliable information which by itself is suffi-
cient to identify ENU-induced mutations selected either by
phenotype or by the nature of the gene that is mutated.
These results provide an immediate source for thousands of
new experimental models for understanding human diseases
and establish a strategy that can be extended for identifying
rare SNVs in outbred mice, humans and other species.3. Results
3.1. Generation and detection of induced, de novo
single-nucleotide variants
Many parallel mouse pedigrees, each segregating a different
set of random, de novo mutations induced in the C57BL/6j
ENU-treated
C57BL/6j male 
ENU-treated
C57BL/6j male 
C57BL/6j
female 
C57BL/6j
female 
G1 progeny
G2 progeny
G3 progeny
Figure 1. Summary of the structure of ENU-mutated mouse pedigrees. Each pedigree is initiated by two unrelated G1 founders. Each of these founders inherits a
random set of de novo point mutations (coloured circles) on the paternal chromosomes, induced by ENU treatment of their male parent. These G1 founders will carry
on average one to two DNA variants per Mb and 90 exonic ENU-induced mutations. Second-generation (G2) progeny of these mice inherit a theoretical 45 ENU-
induced exonic mutations, all of which are carried in the heterozygous state. Two productive sibling – sibling matings of the G2 mice result in third-generation (G3)
progeny that carry approximately 94% of the founding ENU-induced, protein-coding mutations, of which on average five are homozygous in any given mouse.
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shown in figure 1. Each pedigree was founded by two unre-
lated G1 mice conceived from male C57BL/6j mice that had
been treated with three doses of ENU administered at
90 mg kg21 to induce random point mutations in spermato-
gonial stem cells [2,10,11]. Based on published mutation
rates [12–14], we estimated that each of these G1 animals
would carry approximately one de novo SNV per Mb of
the paternal genome, of which around 45 would result in a
non-synonymous exonic mutation. Intercrossing of the G1
animals transmitted half of these mutations in heterozygous
state to each of their second-generation (G2) offspring.
Intercrossing the G2 animals subsequently transmitted
approximately 94 per cent of the mutations to offspring, a
subset of which was inherited in homozygous state in
third-generation (G3) animals (figure 1).
We developed a workflow (figure 2a) to use massively
parallel sequencing reads as a sole data source to identify
exonic ENU-induced mutations in 15 DNA samples taken
from mutated mice (see electronic supplementary material,
table S1). These samples were prepared and enriched for
exonic sequences using either Agilent or Nimblegen sol-
ution-based capture technologies. Each exome sample was
then sequenced as paired-end reads in a full lane of an
Illumina GAIIx sequencer or as a multiplexed, bar-coded
sample in an Illumina HiSeq sequencer, and the resultantreads aligned to the C57BL/6 mouse reference genome
using the BWA aligner [16]. Table S1 in the electronic sup-
plementary material shows the numbers of reads sequenced
and the number of reads aligned to exonic target regions
per sample. The exome capture efficiency was uniformly
high with approximately 40 to 55 per cent of all DNA
sequenced being exonic. Based on a mouse genome size of
2493 Mb [15] and 37 Mb of exonic sequence, using consensus
coding sequence (CCDS) exons [18], this represents on aver-
age a 30.6-fold (s ¼ 3.3) sequence enrichment. Across the
coding portion of the genome sequence, coverage was gener-
ally better than 85 per cent at 5 times depth and better than 70
per cent at 20 times depth, although coverage was distinctly
less for the sex chromosomes (see electronic supplementary
material, figure S1).
Raw SNVs relative to the C57BL/6 reference sequence
were called using SAMTOOLS [17]. In the inbred C57BL/6j
mice we analysed, we would expect the number of true var-
iant calls to be low (approx. 50 exonic SNVs) and almost
entirely due to ENU treatment of the G0 male mouse that
founded their line. However, in each animal, of the order of
10 000 raw SNVs were called across the entire genome, of
which 500–750 SNV calls were located in exons and/or
near exon splice sites (see electronic supplementary material,
table S2). Multiple sources can be attributed to these variant
calls, potentially being due to genetic drift of the C57BL/6j
(a)
exome enrichment
sequencing
align reads to reference
genome (with BWA) 
call raw SNVs versus
reference genome (with
SAMTOOLS)
 
filter for coding or
splicing variants 
filter for non-synonymous
variants 
remove multi-SNV genes
ENU-induced mutations
DNA extraction
raw SNV 
calls 5011
overlap 
exons
overlap 
splice 
sites
574
non-synonymous
387
not in dbSNP
not a common SNV
39
3
3712
87
54
12
360
78
not in a multi-SNV 
gene
3 39
42
homozygous heterozygous
(b)
filter known variation
(dbSNP, common exome
variants)
Figure 2. Workflow and filtering strategy used to identify de novo protein-changing mutations. (a) Following DNA extraction, exome enrichment and sequencing,
reads were aligned to the mouse reference genome [15] using BWA [16] and variation between the two genomes identified using SAMTOOLS [17]. The set of raw
SNVs was subsequently filtered to annotate known variation and other apparent SNVs known not to be ENU-induced. SNVs were further filtered to annotate those
that fell within coding regions (or adjacent splice donor/acceptor sites) and were non-synonymous changes. Finally, as ENU treatment is known to introduce a
uniform genomic distribution of mutations, genes that contained multiple SNVs were filtered from the final set of variants. (b) Using this cumulative filtering
strategy against a single replicate exome sequence of the nimbus mouse, the initial 8723 variant calls reduced to a final set of three homozygous and 39
heterozygous putative mutations. Circles representing homozygous and heterozygous SNV numbers are coloured orange and blue, respectively.
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of sequencing errors in massively parallel sequencing. How-
ever, many of the variants appear to be called because of
technical issues associated with aligning large numbers of
short reads to a large genome containing repeated or highly
similar sequence regions. To reduce these raw variant calls
to a smaller number highly enriched for ENU-induced
mutations, we applied a series of filters to remove known
variants (present in dbSNP) and/or recurrent false-positive
variants (figure 2a). We assert that between multiple, unre-
lated mouse exome sequences, de novo ENU-induced
nucleotide changes should be unique to individual pedigrees,whereas other sources of variants should recur. Based on this
reasoning, we collated a list of SNVs that recurred in more
than one unrelated mouse and found this list to be a very
effective filter for false-positive and potentially sequencer-
and enrichment-specific variants. A further filter was applied
to remove variants where they originate from a gene with
multiple SNV calls, assuming that in any single ENU-
mutated mouse it is highly unlikely that the same gene will
have multiple mutations and that the calls are due to incor-
rect alignment of sequence reads between members of gene
families. Figure 2b shows the efficacy of each individual filter-
ing step applied and the outcome of the filters applied in a
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Figure 3. Sensitivity and specificity of mutation detection in the nimbus mutant mouse pedigree assessed through technical and biological replicate datasets. Venn
diagrams of overlap of filtered variant calls between three technical replicate exome sequence datasets, showing putative (a) homozygous and (b) heterozygous
ENU-induced mutations. The red, green and blue circles each indicate separate technical replicates, and the coloured numbers associated with each denote the total
number of variants called in each dataset. Upper numbers within each sector show the number of filter-passing SNVs called in one, two or all three technical
replicates. The numbers below show the fraction of these SNVs that were validated as true mutations by independent, custom, SNV-specific PCR assays. The
denominator in each case is the number of SNVs where an SNV-specific PCR assay was established successfully. (c) Overlap of filtered variant calls from a set of four
biological replicates, representing two parental G2 nimbus mice and two of their G3 offspring. One of the G3 offspring (labelled G3 proband) is the same mouse as
that sequenced in the technical replicates shown in (a) and (b). The variant numbers shown for this mouse are pooled values from the three technical replicates.
Both G2 nimbus mice and the sibling of the G3 proband (labelled G3 sibling) are unaffected by the lymphopaenia phenotype. Upper numbers within each sector of
the four-way Venn diagram show the total number of filter-passing heterozygous and homozygous SNVs called in one or more of the replicates from this pedigree.
The numbers immediately below show the fractions of biologically replicated SNVs that were validated as true mutations by independent, custom, SNV-specific PCR
assays. In the case of technically replicated data from the proband (the red circle), the third line of data in each region of overlap shows the number of times a
variant was seen in one, two or three replicates (formatted as: single count, double count and triple count).
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 on September 10, 2012rsob.royalsocietypublishing.orgDownloaded from cumulative manner. Overall, from a set of several thousands
of raw variant calls, the cumulative filtering reduced this
number mostly to less than 10 homozygous and 50 heterozy-
gous exonic variants per mouse (see electronic supplementary
material, table S2), closely approximating the expected rate
(figure 1).3.2. Sensitivity and specificity of single-nucleotide
variant detection
To assess the reliability of SNV calls made from a single
exome dataset, we performed a technical and biological repli-
cation experiment on G2 and G3 animals from a pedigree
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some G3 offspring. These nimbus mutant animals displayed a
fourfold reduction in the percentage of CD3þ T cells and
represented 8 of a total of 30 phenotyped individuals,
suggesting that nimbus was a recessive trait. We sequenced
the exome of one proband G3 affected nimbus mouse in tripli-
cate (technical replicates) and also sequenced the exome of
both G2 parents and an unaffected G3 sibling (loosely
termed biological replicates). Figure 3a,b shows that the
SNVs called in each of the technical replicates of the pro-
band’s exome were highly replicable. The total number of
coding changes called in each replicate was 47, 42 and 42,
of which 34 were called in all three replicates, representing
72, 81 and 81 per cent of the SNVs called in each individual
exome analysis. The triplicated SNV calls comprised three
homozygous and 31 heterozygous mutations. We successfully
established custom, SNV-specific PCR assays (Amplifluor
assays; see §5.4) for 50 of the SNVs called in one or more of
these replicates. From 50 successful assays, 100 per cent (28
of 28) of the triplicated SNV calls were validated as true
mutations in this pedigree, whereas of the SNV calls that
were present in only one or two of the replicate analyses
only 14 per cent (3 of 22) were validated and the remainder
were established to be false positives (figure 3a,b and
table 1). From these technical replicate data the false-positive
call rate among our filtered variants can be estimated as
19.4 per cent, calculated from an average of six false-positive
calls per replicate exome as a proportion of the 31
true-positive SNVs.
In mouse spermatogonial stem cells and the mice con-
ceived from the resulting sperm, ENU has been found to
induce a biased set of nucleotide substitutions. Several pre-
vious studies have shown an abundance of TA–CG
transitions and TA–AT transversions (ranging between
36–43% and 22–44% of changes, respectively [2,12,14,19])
and GC–CG transversions very rarely or never occur
[14]. Of the validated 31 true-positive SNVs shown in
table 1, 35.5, 38.7 and 0 per cent were TA–CG, TA–AT
and GC–CG changes, respectively. Of the remaining 19
non-replicated, false-positive SNV calls, 26.3, 0 and 15.8
per cent were TA–CG, TA–AT and GC–CG changes,
respectively.
Exome analysis of the G2 parents of our G3 nimbus pro-
band mouse would be expected to reveal all the true ENU
variants present in the proband mouse. Likewise, approxi-
mately half of the true variants should have also been
inherited by the G3 sibling of the proband. Figure 3c shows
a Venn diagram detailing the overlap between the SNVs
called in the exome sequence of the two parents and sibling
compared with those in the pooled technical replicate
exome sequence of the proband. As expected, all of the
seven homozygous mutations called in the proband or its sib-
ling (three in proband þ four in G3 sibling) were also called
in heterozygous state in both parents. Of the total of 31 vali-
dated mutations present in the G3 proband, 28 were called in
one or both parents (table 1). Inspection of the sequence data
for the two parent G2 exomes revealed that the false-negative
mutations were present, but the number of variant reads fell
below the required coverage and/or read ratio thresholds
used for SNV calling. That three of the 31 true mutations
were not identified in one or more of the replicate analyses
indicates a technical false-negative rate of 9.7 per cent per
exome analysis. However, this estimate does not accommodate
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Figure 4. The influence of sequence quality scores and read depth on the identification of true-positive and false-positive SNVs. (a) False-positive calls with respect to read
depth and quality score, shown for a single exome dataset generated from the G3 nimbus mouse (technical replicate 1 from figure 3). Variant calls on this dataset were
compared with the PCR-validated true-positive and false-positive SNVs called in the technical replicate exome datasets of the G3 nimbus proband. Green and red points are
true- and false-positive SNV calls, respectively. The distribution of read depth frequencies over all exonic bases is indicated by the red line in the top graph. The red bars in the
right-hand graph indicate the distribution of quality scores also ascertained for all exonic bases. (b) Results of simulation experiment performed to generate random subsets of a
single exome dataset, being one of the triplicate exome runs for the nimbus proband (technical replicate 1). The panel shows tallies of true-positive heterozygous (green), false-
positive heterozygous (red), true-positive homozygous (blue) and false-positive homozygous (grey) SNV calls plotted against the number of input reads, which are incremental
proportions of an Illumina GAIIx lane. Numbers alongside the green dots indicate the median read depth determined for each true-positive data point. Plotted above are the
proportions of the exome covered at 20 depth or better for each proportion of the input read set.
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ently because they lie in exons that are inefficiently captured
and exhibit low sequence coverage.
The false-negative rate of SNV detection can also be esti-
mated from the distribution of sequence read depths
generated at random across a whole genome. The depth of
reads obtained from random short-read sequencing approxi-
mates a Poisson distribution and the probability of observing
both alleles at a single site in a diploid genome is a binomial
function of read depth [20,21]. A combination of these two
distributions can be used to estimate the false-negative SNV
call rate based simply on the mean read depth [20–22].
While the distribution of read depths obtained from exome
capture appears to be mostly Poisson distributed, this
approximation does not hold for sites that are poorly
enriched by hybridization to exomic baits (see electronic sup-
plementary material, figure S2), which are also the sites
where low coverage is likely to result in the greatest incidence
of false-negative calls. In order to estimate an accurate false-
negative SNV call rate we used the observed distribution of
sequence read depths rather than that derived from a Poisson
function. In this manner, we calculated the false-negative
SNV call rate in the nimbus G3 proband mouse as 21.3 percent. The average read depth from this dataset was 39.5,
but 14.6 per cent of CCDS exomic bases were not covered
at all, this being the major source of missing SNV calls.
Increasing the amount of sequence data does reduce the
false-negative rate slightly, but still a large number of geno-
mic sites will remain poorly covered, either owing to it
being difficult to design capture baits to these regions or
owing to extreme GC content reducing the efficiency of
hybridization of some areas of the genome (data not shown).
Taking the SNV calls from a single replicate exome from
the nimbus proband G3 mouse, we investigated whether or
not validated true- and false-positive SNVs differed in
sequence coverage or quality. Figure 4a shows that false-posi-
tive SNVs had unusually high or low read depth, or had
lower quality scores, relative to the depth and quality of
reads across all exonic nucleotides. However, in these data
the read depths and quality scores of false-positive variants
overlap with those of true-positive calls. While we have
chosen to minimize the false-negative rate as much as
possible, if it were desirable to reduce the false-positive call
rate at the expense of the false-negative rate, this could
potentially be achieved with more stringent filtering against
read depth and quality score.
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we simulated an exome sequencing experiment where incre-
mental proportions of one lane of exome sequence reads were
randomly sampled from a full lane of G3 nimbus exome data
(figure 4b). While reliable homozygous variant calls (blue
dots in figure 4b) were made at even shallow read depths, a
substantially greater depth was required for reliable hetero-
zygous variant calls. True-positive heterozygous variant
calls (green dots in figure 4b) increased significantly with
increasing depth up to a total of 30 million reads. Ninety-
three per cent of true-positive mutations were detected with
35–40 million reads (22–26 times median depth). With
increasing the read depth beyond this value, relatively few
additional true positives were called but the number of
false-positive heterozygous SNV calls doubled.
3.3. Functional validation of causative mutation in
nimbus strain
To identify the mutation causing the recessive lymphopaenia
phenotype in the nimbus strain, we performed Amplifluor
assays on each of the three homozygous mutations identified
in the proband exome sequence to trace their inheritance in
the pedigree. Homozygosity for a C-to-T mutation identified
at Chr1 : 139 986 182 bp was found to co-segregate with the
lymphopaenia phenotype (table 2). This change lies 1 bp
upstream of exon 18 of the Ptprc gene and disrupts the intro-
nic-1 G nucleotide of the consensus splice acceptor sequence
[34], which is otherwise absolutely conserved across ver-
tebrates. PCR amplification of the mutant Ptprcnim mRNA
showed the first 14 bp of exon 18 were deleted compared
with the spliced wild-type mRNA and putatively the AG
nucleotides at þ13 to 14 of exon 18 from an alternative splice
acceptor site. This altered splicing leads to a frameshift in the
mutant transcript from the truncated start of exon 18 onwards.
Ptprc encodes the CD45 protein, which is a tyrosine phospha-
tase receptor type C. CD45 is an abundant protein in the
plasma membrane of leukocytes and plays critical roles in lym-
phocyte development in mice and humans (reviewed in [35]).
Mice homozygous for the Ptprcnim mutation indeed had almost
no CD45 protein on the surface of their B-lymphocytes (2% of
wild-type controls) as measured by flow cytometric staining
with antibodies to CD45 (figure 5b), while heterozygous
mice showed an approximately 50 per cent reduction in the
expression of CD45. The lymphopaenia in nimbus homozy-
gotes matches that in mice and humans with other null or
severe loss-of-function mutations in Ptprc [29,36,37].
3.4. Identification of causal mutations in
11 additional strains
The successful use of exome analysis to identify causative
mutations without meiotic mapping was repeated for 11
other ENU pedigrees with immune disorders or obesity, apply-
ing the same analysis to individual exome sequences from
proband G3, G4 or G5 mice (table 2). In each of these pedigrees,
the causative mutation was revealed solely using exome
sequence data followed by SNV-specific Amplifluor PCR
typing to correlate the SNV genotypes with the phenotype in
the pedigree, without the need for meiotic mapping. The
mutations found in each of these strains variously included pre-
mature stop codons, disrupted splice donor or acceptor sitesand missense changes. The correlation between genotype and
phenotype, together with the similar phenotype of independent
mutant alleles of the same genes, provided strong corroboration
that the mutations identified by exome sequencing were indeed
responsible for the phenotypes observed in these mice.
A mean of 6 homozygous and 36 heterozygous mutations
were called in the exome sequence of each of the proband
individuals from the strains analysed in table 2. These num-
bers are small enough to contemplate exhaustive validation
of each SNV and typing of siblings by Amplifluor PCR
assays to test phenotype–genotype concordance, although
in many cases a knowledge of the function of the mutant
genes allowed candidate mutations to be prioritized. Of the
nine strains for which a recessive mutant was sought, the cau-
sative variant needed to be selected from on average only 6.4
(s ¼ 3.8) candidate mutations. Two of the strains required the
causative variant to be identified in a heterozygous form. In
these two strains the heterozygous candidate mutation lists
were tractably just 40 and 13 variants long.
The incidental mutations revealed by exome sequencing
of proband mice in each pedigree represent a remarkable
resource for gene-driven testing for other phenotypes.
On average, 35.5 (s ¼ 13.7) heterozygous exonic mutations
were identified in the G3, G4 and G5 mice presented in
table 2. Applying the false-positive rate of 19.4 per cent
deduced above, on average each G3, G4 or G5 mutant
mouse will carry around 29 incidental heterozygous
mutations. This gene-driven strategy was successfully
reduced to practice in the strain ENU16NI3b, where the orig-
inal phenotype of low KLRG1 protein on the surface of NK
cells occasionally co-occurred with ashen coat colour or
stunted growth, neither of which could be explained by a
mutation in the KLRG1 gene. With reference to the mutation
list obtained from exome sequencing of the G3 proband
mouse in this strain, two additional incidental mutations
were found by Amplifluor PCR to segregate with each inci-
dental phenotype. A homozygous missense mutation in
Rab27a co-segregated with ashen coat colour in this pedigree,
and an independent Rab27a mutation has previously been
shown to cause the same trait through a defect in melano-
some transport [31]. A homozygous nonsense mutation in
the thyroglobulin gene, TgR1471X, was found to co-segregate
in the same pedigree with stunted growth, and this comp-
lements an independent study that showed that a
spontaneous missense mutation in the Tg gene caused
stunted growth, hypothyroidism and goiter in an AKR
mouse substrain [32]. The new TgR1471X strain provides a
C57BL/6j mouse model for human thyroid dyshormono-
genesis 3 syndrome (OMIM: 274700), which was first
shown to result from a similar R1510X nonsense mutation
in thyroglobulin [38].
3.5. Mutant first-generation mouse resource
The sensitivity and specificity of detecting heterozygous
de novo mutations established above opened up a broader
strategy to develop mouse experimental models based on
tracking specific mutations in gene-driven phenotypic
screens, as had been done for the Tg and Rab27a mutations.
To make it possible to do this in a systematic way, we
extended the exome sequencing approach to identify novel
protein-changing mutations arising in the G1 founders of
ENU mutagenized pedigrees, prior to any phenotypic
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all the mutations are heterozygous (figure 1). We sequenced
the enriched exomes of eight different G1 mice as a bar-
coded, pooled sample on an Illumina HiSeq sequencing
run. This provided a greater number of reads per exome
than the datasets generated on the GAIIx sequencers, and
yielded better than 20 times sequence depth over 80.7 per
cent (s ¼ 1.8%) CCDS exons. As expected, very few homozy-
gous variants were identified in the filtered variant lists,
presumably being rare variants previously unobserved in
the parental C57BL/6j stock. The numbers of heterozygous
variants in the G1 mice (m ¼ 59.6, s ¼ 13.1) were higher
than those found in G3, G4 or G5 mice (m ¼ 36.5, s ¼ 13.7;
table 2), which was as expected since a fraction of ENU-
induced alleles will be lost in each subsequent generation
owing to random drift and purifying selection. Hence,
given the information presented in figure 4b, we would
expect that the majority of true ENU-induced mutations
have been detected from these datasets.
Of the 454 unique mutations detected across these eight
G1 mice, 18 (4%) created a premature stop codon, 65 (14%)
putatively disrupted an mRNA splice donor/acceptor site
and 370 (81%) caused an amino acid substitution (see elec-
tronic supplementary material, table S4). We altered
PolyPhen2 [39] to use mouse sequence databases (rather
than the default human inputs) and calculated scores for mis-
sense G1 mutations. Figure 6 shows a comparison of these
scores with those calculated for a set of previously character-
ized ENU-induced mutations known to cause immunological
traits. For the causal missense mutations, PolyPhen2 correctly
assigned a very high score (greater than 0.95) of ‘probably
damaging’ to 75 per cent and an intermediate to high score
(0.44–0.95) of ‘possibly damaging’ to a further 15 per cent.
This result validates the predictive accuracy of PolyPhen2
when applied to novel mouse mutations. Of the 370 de
novo missense mutations identified in G1 mice, 134 (36%)
were assigned a ‘probably damaging’ score of greater than
0.95 and 59 (16%) were classified as ‘possibly damaging’
with a score of 0.505–0.897. The genes affected by these
272 potentially damaging mutations include those known
to cause human disease through to entirely unexplored
genes with intriguing expression patterns and protein
domains (see electronic supplementary material, table S3).
By identifying de novo ENU mutations in G1 founders in
this way and then breeding, genotyping and phenotyping
their G2 and G3 offspring, this approach provides an
immediate source for new experimental models for
understanding human diseases and traits.4. Discussion
The pursuit of gene function that starts with the identification
of medically important phenotypes displayed by individual
mammals (the so-called forward-genetics) has until now
been constrained by the time-consuming and expensive bot-
tleneck of mapping these traits to their underlying genetic
cause. Conversely, reverse genetics approaches based on
knocking out individual genes in embryonic stem cells
remain constrained by a comparably time-consuming and
expensive bottleneck of converting the embryonic stem cells
into a pedigree of mice that can be phenotypically evaluated.
Here we have shown that exome capture followed by
CD45R
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Figure 5. Nimbus results from a loss of function mutation in the Ptprc gene. (a) Schematic diagram showing the location of single nucleotide mutation at
Chr1:139986183 at the þ1 intronic position of the exon 17 splice donor sequence and the location of the corresponding region in the encoded CD45 protein (TM,
transmembrane domain; FNIII, fibronectin III-like domain; PTP, protein tyrosine phosphatase). (b) Loss of CD45 protein expression. Bold black lines show flow
cytometric staining with antibody to the B-cell-specific CD45R isoform on IgMþ, IgDþ B lymphocytes in blood from (i) Ptprcþ/þ wild-type (wt), (ii) Ptprcnimbus/þ
heterozygous or (iii) Ptprcnimbus/nimbus homozygous mouse, compared with negative control staining on CD3þ T cells in the same mouse (thin black line) and
compared with positive control staining with the same antibody on B cells in a wt mouse (grey shaded area).
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the majority of homozygous and heterozygous ENU-induced
mutations. Not only does this eliminate the bottleneck to for-
ward genetics by identifying causal mutations without the
need for meiotic mapping, but also it bypasses a key restric-
tion for reverse genetics by revealing thousands of possibly
damaging mutations in live-breeding C57BL/6j mouse pedi-
grees that are immediately available for experimental analysis
of gene function.
By technical and biological replication of exome analyses
and confirmation of individual SNV calls by PCR, we have
shown that both homozygous and heterozygous protein-
changing mutations induced by ENU de novo in live-breed-
ing pedigrees of C57BL/6j mice can be called reliably with
an estimated sensitivity of 78.7 per cent and a specificity of
80.6 per cent. In 11 separate C57BL/6j mutant strains from
forward genetics screens for immune system disorders or
obesity, we were able to bypass the need for meiotic mapping
and identify short lists of protein-changing ENU-induced
mutations that were heterozygous or homozygous inproband individuals from these pedigrees, among which
we were able to identify a causative mutation that explained
the immunological or obesity phenotype. In identifying
ENU-induced mutations, we found massively parallel
sequencing data to be highly reliable and sources of error
were predictable, such that by filtering commonly called var-
iants (along with previously observed genetic variation) we
were able to restrict the false-positive call rate to less than
20 per cent while not incurring a disproportionate false-nega-
tive call rate. In terms of the read depth required to reliably
identify heterozygous mutations, we found that around 35
million paired-end sequence reads are sufficient to identify
more than 90 per cent of these changes.
Fairfield et al. [9] have also produced an extensive demon-
stration of exome capture and sequencing in mice to identify
causative mutations. In their study, exome sequence data
were used in combination with meiotic mapping information
to identify causal mutations without a large validation
burden. Our results both confirm and extend this study.
Laudably, the Fairfield et al. [9] study describes three
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Figure 6. Violin plot comparing PolyPhen2 scores for incidental and causative
mutations. The black bars represent a boxplot where 50% of values lie within the
main bar. The white dot indicates the median polyphen value for each set of scores.
The blue region is a kernel density plot representing the distribution of PolyPhen2
scores. The numbers of mutations included in the plot were: incidental mutations,
n ¼ 325 and causative mutations, n ¼ 40. A Mann – Whitney test for the
equality of the mean PolyPhen2 score of the incidental and causative mutations
indicated a significant difference in score (W ¼ 4168, p¼ 0.0000862).
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even with the aid of meiotic mapping information. They
speculated that, in those strains where the causal mutation
could not be identified, it probably lay outside the chromo-
somal regions enriched by exome capture. Our analysis
provides further insight into this problem and shows that,
in approximately one of five mouse strains, we can expect a
causal mutation to remain undetected owing to it not being
efficiently captured prior to sequencing and/or subsequently
detected. We found that solution capture methods commer-
cialized by Agilent and Nimblegen are both effective at
specifically concentrating the coding part of the mouse
genome, but that a consistent approximately 15 per cent por-
tion of exonic regions is absent from subsequently sequenced
reads, regardless of how deeply the captured DNA is
sequenced. This may be a fundamental limitation of exome
enrichment technologies, perhaps indicating that some geno-
mic regions may be resistant to efficient hybridization with
capture baits and/or the PCR amplification steps in the cap-
ture and library preparation protocols. From analysis of
exome datasets from related mice, in a small number of
cases known heterozygous variants were only poorly
detected owing to a very few reads supporting the mutant
genotype. This effect may indicate that in some local
sequence contexts the mutant genotype is out-competed by
the reference genotype during sequence capture.
Mutated C57BL/6j inbred mice provide an ideal system
for tackling the challenges of identifying rare, de novo
mutations from a background of normal genetic variation.
While the laboratory mouse is an inbred organism with very
little genetic variation, we found that it was necessary to con-
trol for even this small amount of variation through a series of
data filtering strategies employing catalogues of known strain
variants and other sources or recurring false positives in order
to identify true mutations with high specificity. Givensufficient data for a specific mouse strain (10–20 individual
exome sequences), this strategy of cataloguing recurrent var-
iants has also proven effective in identifying ENU-induced
mutations in mice out-crossed to strains other than C57BL/6j
(data not shown). We found that detection of ENU-induced
mutations can be further enhanced by technical replication of
exome analysis and by biological replication taking advantage
of heritability information in closely related individuals. Taken
together, this information makes pathogenic mutation detec-
tion in outbreeding mammals (such as humans) a more
tractable possibility.
We have shown that it is feasible to also perform these
exome analyses in multiplexed, bar-coded samples from
many separate G1 founder mice. This makes it straightfor-
ward to analyse the exomes of hundreds of G1 founder
mice per year and propagate the mutations they carry in
live-breeding pedigree structures such as the ones employed
here (figure 1). Given the number of protein-changing
mutations we identified in each G1 mouse (table 3), a live-
breeding resource of 350 pedigrees bred for two generations
from 700 G1 mice each year would reveal 42 000 new
protein-changing mutations per year, of which around half
are expected to be deleterious. Hence, reliable identification
of induced mutations has the potential to transform genetic
screens of genes of unknown function and produce mouse
models of hundreds of human diseases.5. Material and methods
5.1. Mutant mouse generation
The nimbus mouse strain was generated by treating pure
C57BL/6j male mice with the mutagen ENU at the Australian
Phenomics Facility of the Australian National University as pre-
viously described [10]. Briefly, adult male animals received
90 mg of ENU per kilogram of body weight by three weekly
intraperitoneal injections. Once fertility was regained after a
further eight weeks, the animals were mated with C57BL/6j
females to generate G1 offspring carrying a unique cohort
of heterozygous SNVs. A subset of SNVs was brought to
homozygosity through unrelated G1 crosses followed by inter-
crossing to G3 (as shown in figure 1). A peripheral blood screen
for lymphocyte subsets identified the nimbus strain at G3 as dis-
playing a mild lymphopaenia. All other mutated mouse strains
sequenced were generated via this protocol.
5.2. Exome enrichment and sequencing
DNA was extracted from ear tissue of affected mice and 3.5 mg
prepared as paired-end genomic libraries (PE-102-1001: Illu-
mina, San Diego, CA). Technical replicates were produced
from the same DNA sample. Exome enrichment was per-
formed using either the SureSelect Mouse Exome kit
(G7550A-001: Agilent, CA) or the SeqCap Mouse Exome kit
(early access: Nimblegen, Madison, WI) following the
manufacturer protocols. Four amplification cycles were used
in the library pre-capture PCR using Herculase II fusion
polymerase (600677, Stratagene) and eight cycles in the post-
enrichment amplification for both capture technologies.
Enriched libraries were diluted to 10 nM concentrations
before further dilution to 7–8 pM for cluster generation and
sequencing-by-synthesis on either the Illumina Genome
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reads. Each library sequenced on an Illumina GAIIx was
sequenced on a single lane of an eight-lane flow-cell, whereas
libraries sequenced on the Illumina HiSeq were multiplexed
in a pool of 10 samples and sequenced together, and disambig-
uated using sample bar-coding.ypublishing.org
Open
Biol2:1200615.3. Single-nucleotide variant detection workflow
A custom workflow was developed to process sequence
reads to detect ENU-induced mutations. This workflow
holds together a number of open-source analysis tools and
employs a Perl code-base to perform custom filtering, report-
ing and job process control (figure 2a). BWA (v. 0.5.9-rc16;
[16]) with default settings was chosen to align paired-end
reads to the reference mouse genome (mm9/NCBIM37).
Reads aligning to multiple genomic locations were removed
and raw SNV calls were made using SAMTOOLS (v. 0.1.15;
[17]) with parameters set to allow a less conservative calling
rate than the default settings, which significantly involved
disabling the base alignment quality filtering function. Raw
SNV calls were classified as homozygous or heterozygous on
the basis of the ratio of alleles (hom . 0.8 variant allele; het
two alleles . 0.3) and then annotated as to whether they
were also present in dbSNP (v. 128; http://www.ncbi.nlm.
nih.gov/snp/), whether they commonly occurred in our
exome data and, where appropriate, whether they were
strain-specific variants identified from the Sanger Institute
mouse genomes sequencing project (http://www.sanger.ac.
uk/resources/mouse/genomes/). Commonly occurring var-
iants were collated from all exome data collected by our
laboratory. Further annotation of variants was performed to
determine overlap with CCDS exons [18] and denote non-
synonymous changes (using ANNOVAR [40]). Changes that
lay in potential splice donor–acceptor sites immediately adja-
cent to exon boundaries (out to 10 intronic bases) were also
annotated. Using these annotations, we filtered the variant
list to only include non-synonymous or splice donor–accep-
tor site changes that were novel to a particular sample.
From this filtered list of variants, for each exome a list of
genes containing more than one variant was compiled for
each sample and then used to further filter variants across
all samples that were found in these multi-SNV genes.5.4. Variant validation
SNVs were validated using Amplifluor assays (Chemicon,
Temecula, CA). Primers were designed using the Assay
architect online tool (http://apps.serologicals.com/AAA/
mainmenu.aspx). Fluorescent intensities were detected
using a Fluostar optima (BMG). The individual affected
mice used in the study and a C57BL/6j control were analysed
for each SNV assay.6. Acknowledgements
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